Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012:2012:823085.
doi: 10.1155/2012/823085. Epub 2012 Jun 14.

Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new

Affiliations
Review

Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new

Alessia Alunno et al. Clin Dev Immunol. 2012.

Abstract

Pathogenic mechanisms underlying the development of systemic lupus erythematosus (SLE) are very complex and not yet entirely clarified. However, the pivotal role of T lymphocytes in the induction and perpetuation of aberrant immune response is well established. Among T cells, IL-17 producing T helper (Th17) cells and regulatory T (Treg) cells represent an intriguing issue to be addressed in SLE pathogenesis, since an imbalance between the two subsets has been observed in the course of the disease. Treg cells appear to be impaired and therefore unable to counteract autoreactive T lymphocytes. Conversely, Th17 cells accumulate in target organs contributing to local IL-17 production and eventually tissue damage. In this setting, targeting Treg/Th17 balance for therapeutic purposes may represent an intriguing and useful tool for SLE treatment in the next future. In this paper, the current knowledge about Treg and Th17 cells interplay in SLE will be discussed.

PubMed Disclaimer

References

    1. Tsokos GC. Mechanisms of disease: systemic lupus erythematosus. New England Journal of Medicine. 2011;365(22):2110–2121. - PubMed
    1. D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. The Lancet. 2007;369(9561):587–596. - PubMed
    1. O’Neill S, Cervera R. Systemic lupus erythematosus. Best Practice and Research. 2010;24(6):841–855. - PubMed
    1. Sanz I, Lee FEH. B cells as therapeutic targets in SLE. Nature Reviews Rheumatology. 2010;6(6):326–337. - PMC - PubMed
    1. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunology. 2005;6(11):1133–1141. - PMC - PubMed